Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide +/- Prednisone in Myelofibrosis
NCT00946270Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2009
- Primary completion
- May 2018
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide in myelofibrosis (MF) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Best Overall Response at 6 months. Started Jul 2009; status: completed.
02
Drugs
pomalidomide
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00946270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00946270.